131 related articles for article (PubMed ID: 11216561)
21. Use of bolus intraperitoneal aminoglycosides for treating peritonitis in end-stage renal disease patients receiving continuous ambulatory peritoneal dialysis and continuous cycling peritoneal dialysis.
Mars RL; Moles K; Pope K; Hargrove P
Adv Perit Dial; 2000; 16():280-4. PubMed ID: 11045311
[TBL] [Abstract][Full Text] [Related]
22. Histologic change of peritoneal membrane in relation to adequacy of dialysis in continuous ambulatory peritoneal dialysis patients.
Savidaki I; Karavias D; Sotsiou F; Alexandri S; Kalliakmani P; Presvelos D; Papachristou E; Goumenos DS; Vlachojannis JG
Perit Dial Int; 2003 Dec; 23 Suppl 2():S26-30. PubMed ID: 17986552
[TBL] [Abstract][Full Text] [Related]
23. Time dependence of solute removal during a single exchange.
Wang T; Heimbürger O; Waniewski J; Bergström J; Lindholm B
Adv Perit Dial; 1997; 13():23-8. PubMed ID: 9360645
[TBL] [Abstract][Full Text] [Related]
24. Disposition and bioavailability of ceftazidime after intraperitoneal administration in patients receiving continuous ambulatory peritoneal dialysis.
Stea S; Bachelor T; Cooper M; de Souza P; Koenig K; Bolton WK
J Am Soc Nephrol; 1996 Nov; 7(11):2399-402. PubMed ID: 8959631
[TBL] [Abstract][Full Text] [Related]
25. Stability and Compatibility of Antibiotics in Peritoneal Dialysis Solutions Applied to Automated Peritoneal Dialysis in The Pediatric Population.
Deslandes G; Grégoire M; Bouquié R; Le Marec A; Allard S; Dailly E; Pineau A; Allain-Launay E; Jolliet P; Roussey G; Navas D
Perit Dial Int; 2016 11-12; 36(6):676-679. PubMed ID: 27147292
[TBL] [Abstract][Full Text] [Related]
26. Stability of Antibiotics for Intraperitoneal Administration in Extraneal 7.5% Icodextrin Peritoneal Dialysis Bags (STAB Study).
Ranganathan D; Naicker S; Wallis SC; Lipman J; Ratanjee SK; Roberts JA
Perit Dial Int; 2016; 36(4):421-6. PubMed ID: 26493753
[TBL] [Abstract][Full Text] [Related]
27. Small and middle molecular weight solute clearance in nocturnal intermittent peritoneal dialysis.
Brophy DF; Sowinski KM; Kraus MA; Moe SM; Klaunig JE; Mueller BA
Perit Dial Int; 1999; 19(6):534-9. PubMed ID: 10641773
[TBL] [Abstract][Full Text] [Related]
28. Treatment and outcome of peritonitis in automated peritoneal dialysis, using a once-daily cefazolin-based regimen.
Fielding RE; Clemenger M; Goldberg L; Brown EA
Perit Dial Int; 2002; 22(3):345-9. PubMed ID: 12227392
[TBL] [Abstract][Full Text] [Related]
29. Does intraoperative blood loss affect antibiotic serum and tissue concentrations?
Swoboda SM; Merz C; Kostuik J; Trentler B; Lipsett PA
Arch Surg; 1996 Nov; 131(11):1165-71; discussion 1171-2. PubMed ID: 8911256
[TBL] [Abstract][Full Text] [Related]
30. Effects of intraperitoneal cefazolin on mesothelial cells in noninfected CAPD patients.
Manley HJ; Bailie GR
Perit Dial Int; 2001; 21(1):83-5. PubMed ID: 11280503
[No Abstract] [Full Text] [Related]
31. Comparison of Change in Peritoneal Function in Patients on Continuous Ambulatory PD vs Automated PD.
Samad N; Fan SL
Perit Dial Int; 2017; 37(6):627-632. PubMed ID: 28970363
[TBL] [Abstract][Full Text] [Related]
32. Initial treatment of peritoneal dialysis peritonitis without vancomycin with a once-daily cefazolin-based regimen.
Goldberg L; Clemenger M; Azadian B; Brown EA
Am J Kidney Dis; 2001 Jan; 37(1):49-55. PubMed ID: 11136167
[TBL] [Abstract][Full Text] [Related]
33. Systemic absorption of intraperitoneal antimicrobials in continuous ambulatory peritoneal dialysis.
O'Brien MA; Mason NA
Clin Pharm; 1992 Mar; 11(3):246-54. PubMed ID: 1611814
[TBL] [Abstract][Full Text] [Related]
34. Peritoneal dialysis kinetic modeling: validation in a multicenter clinical study.
Vonesh EF; Burkart J; McMurray SD; Williams PF
Perit Dial Int; 1996; 16(5):471-81. PubMed ID: 8914177
[TBL] [Abstract][Full Text] [Related]
35. Peritoneal urea and creatinine clearances in continuous peritoneal dialysis patients with different types of peritoneal solute transport.
Tzamaloukas AH; Murata GH; Piraino B; Rao P; Bernardini J; Malhotra D; Oreopoulos DG
Kidney Int; 1998 May; 53(5):1405-11. PubMed ID: 9573559
[TBL] [Abstract][Full Text] [Related]
36. Pharmacokinetics of intraperitoneal gentamicin in peritoneal dialysis patients with peritonitis (GIPD study).
Varghese JM; Roberts JA; Wallis SC; Boots RJ; Healy H; Fassett RG; Lipman J; Ranganathan D
Clin J Am Soc Nephrol; 2012 Aug; 7(8):1249-56. PubMed ID: 22700884
[TBL] [Abstract][Full Text] [Related]
37. An in vivo-in vitro study of cefepime and cefazolin dialytic clearance during high-flux hemodialysis.
Maynor LM; Carl DE; Matzke GR; Gehr TW; Farthing C; Farthing D; Brophy DF
Pharmacotherapy; 2008 Aug; 28(8):977-83. PubMed ID: 18657014
[TBL] [Abstract][Full Text] [Related]
38. Pharmacokinetics of once-daily IP gentamicin in CAPD patients.
Low CL; Bailie GR; Evans A; Eisele G; Venezia RA
Perit Dial Int; 1996; 16(4):379-84. PubMed ID: 8863331
[TBL] [Abstract][Full Text] [Related]
39. Selected growth factors in peritoneal dialysis: their relationship to markers of inflammation, dialysis adequacy, residual renal function, and peritoneal membrane transport.
Stompór T; Zdzienicka A; Motyka M; Dembińska-Kieć A; Davies SJ; Sulowicz W
Perit Dial Int; 2002; 22(6):670-6. PubMed ID: 12556068
[TBL] [Abstract][Full Text] [Related]
40. Independent effects of residual renal function and dialysis adequacy on nutritional status and patient outcome in continuous ambulatory peritoneal dialysis.
Szeto CC; Lai KN; Wong TY; Law MC; Leung CB; Yu AW; Li PK
Am J Kidney Dis; 1999 Dec; 34(6):1056-64. PubMed ID: 10585315
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
